Skip to main content
Premium Trial:

Request an Annual Quote

Quest Makes Equity Investment in Correlogic

NEW YORK, June 9 (GenomeWeb News) - Quest Diagnostics has made an equity investment in Correlogic Systems, the companies said today.


The companies declined to disclose the amount of funding.


Quest retains an option to commercialize specific Correlogic diagnostics for particular disease states, the companies said. The company has also licensed Correlogic's OvaCheck for commercialization, the companies said.


OvaCheck was the subject of a February letter sent to Correlogic by Steve Gutman, director of the US Food and Drug Administration's Office of In Vitro Diagnostic Device Evaluation and Safety notifying the company that the diagnostic may be subject to the agency's premarket review requirements.


OvaCheck is now in validation testing, Correlogic said.


Correlogic is also developing a prostate cancer diagnostic with the UniformedServicesUniversityof the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine based on the company's protein pattern-recognition approach, the company said in May.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.